Shingles Vaccine May Offer Protection Against Dementia, Studies Suggest

Recent large-scale studies indicate a potential link between the shingles vaccine and a reduced risk of dementia, with some research suggesting a decrease of up to 20%. The findings have generated significant interest among researchers and the public, leading to a notable increase in demand for the vaccine in the UK. While the vaccine is primarily designed to prevent the painful viral disease shingles, which is caused by the reactivation of the varicella-zoster virus, emerging research suggests it might also offer neuroprotective benefits.

One significant study from Stanford University, published in April of last year, utilized a policy change in Wales regarding vaccine eligibility. By comparing individuals close in age but differing in their eligibility for the shingles vaccine, researchers observed a lower rate of new dementia diagnoses over a seven-year follow-up period among those who received the vaccine. They estimated this reduction in risk to be around 20%, with a particularly pronounced effect noted in women. The reasons for this gender difference remain unclear and require further investigation.

Another study, led by Oxford University researchers and published in Nature Medicine in 2024, examined the newer Shingrix vaccine. Analyzing medical records of over 200,000 individuals in the US, the study found that recipients of Shingrix had a lower incidence of dementia diagnoses compared to those who received an older vaccine, Zostavax. This research suggested that Shingrix was associated with an approximately 17% increase in the time to dementia diagnosis, translating to an average of 164 additional days without the disease. Similar to the Stanford study, this research also indicated a stronger effect in women.

Scientists are exploring several hypotheses for this potential link. One theory suggests that preventing the reactivation of the shingles virus might reduce inflammatory processes that can affect the nervous system and brain health. Inflammation and immune system changes are known to be involved in neurodegenerative diseases like Alzheimer's. Another hypothesis is that the vaccine broadly influences immune system activity beyond just protection against the virus. However, these mechanisms are not yet fully understood, and the vaccine's effect on the accumulation of Alzheimer's-related proteins has not been proven.

Despite the encouraging findings, experts caution that it is too early to recommend the shingles vaccine specifically for dementia prevention. Organizations like Alzheimer's Research UK emphasize that while the results are promising, direct causal evidence is still lacking. Current recommendations for reducing cognitive decline risk include regular exercise, a balanced diet, managing blood pressure and diabetes, avoiding smoking, and maintaining social and cognitive activity. Ongoing clinical trials are expected to provide more definitive answers on whether the shingles vaccine offers additional benefits beyond its established role in preventing shingles and its complications.